Case Reports in Dermatological Medicine
Volume 2016 (2016), Article ID 7296572, 3 pages
http://dx.doi.org/10.1155/2016/7296572

Case Report

Acquired Localized Hypertrichosis Induced by Rivastigmine

Adrian Imbernón-Moya,¹ Sebastian Podlipnik,² Fernando Burgos,³ Elena Vargas-Laguna,¹ Antonio Aguilar-Martínez,¹ Eva Fernández-Cogolludo,¹ and Miguel Angel Gallego-Valdes¹

¹Department of Dermatology, Hospital Universitario Severo Ochoa, Avenida de Orellana, Leganés, 28911 Madrid, Spain
²Department of Dermatology, Hospital Clinic, Carrer de Villarroel 170, 08036 Barcelona, Spain
³Department of Pathology, Hospital Universitario Severo Ochoa, Avenida de Orellana, Leganés, 28911 Madrid, Spain

Received 19 January 2016; Revised 24 February 2016; Accepted 7 March 2016

Academic Editor: Jeung-Hoon Lee

Copyright © 2016 Adrian Imbernón-Moya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Hypertrichosis is the excessive hair growth in any area of the skin surface. Acquired localized hypertrichosis may be secondary to multiple causes and there is a secondary form due to several drugs, which is usually reversible with discontinuation of the causative agent. Rivastigmine is a reversible and competitive inhibitor of acetylcholinesterase and butyrylcholinesterase used for symptomatic treatment of Alzheimer dementia and Parkinson’s disease. It has an adequate safety profile and cutaneous side effects are unusual. Irritant contact dermatitis, allergic dermatitis, baboon syndrome, and cutaneous rash due to rivastigmine have been reported. We report on a Caucasian 80-year-old male with personal history of Alzheimer’s disease. The patient started therapy with oral rivastigmine one month prior to clinical presentation of localized hypertrichosis on both forearms. Norgalanthamine has been shown to promote hair growth activity via the proliferation of dermal papilla. Acetylcholinesterase inhibitors can induce hair growth.

1. Introduction

Irritant contact dermatitis, allergic dermatitis, baboon syndrome, and cutaneous rash due to rivastigmine have been reported. However, to our knowledge, no description of rivastigmine producing hypertrichosis is reported in the literature to date. We report a case of drug-induced acquired localized hypertrichosis associated with oral rivastigmine use.

2. Case Presentation

We report the case of a Caucasian 80-year-old male referred to the Dermatology Department due to progressive asymptomatic hair growth on both forearms for three months. He had a personal history of chronic obstructive pulmonary disease and Alzheimer’s disease with severe cognitive impairment, with no family or dermatological history. The patient denied sun exposure, infection, trauma, bites, or contact with chemicals, but he started taking oral rivastigmine (3 mg every 12 hours) one month prior to clinical presentation of the hypertrichosis. The patient denied taking other drugs.

Dermatological examination showed increased density of pigmented and thickened terminal hair and several actinic keratoses on his dorsal sides of forearms with symmetrical distribution (Figures 1(a) and 1(b)). There were no other cutaneous findings and general physical examination was normal.

(a)

(b)

(c)

Figure 1: (a) Increased density of pigmented and thickened terminal hair in the forearms. (b) Increased density of pigmented and thickened terminal hair in the forearms. (c) Terminal medullated and pigmented hair follicle in the dermis without apparent alteration (hematoxylin and eosin, ×4).

All the following laboratory evaluations were in the normal range: biochemical parameters, complete blood cell count, hemostasis albumin, serum protein electrophoresis, thyroid-stimulating hormone (TSH), testosterone, dihydrotestosterone, dehydroepiandrosterone sulphate (DHEAS), androstenedione, cortisol, L-lactate dehydrogenase (LDH), beta-2-microglobulin, and tumor markers (PSA, CEA, CA 19.9, and CA 125). Syphilis serology, HCV, HBV, and HIV were negative. The chest radiograph and abdominal ultrasound did not show any pathological findings.

Microscopic analysis of a hair sample did not show any abnormalities in its structure. Histologic examination of the hair follicles obtained from a punch biopsy demonstrated that the hairs were of terminal type since they were medullated and pigmented and penetrated deep into the dermis. No apparent alteration was observed (Figure 1(c)).

Due to normal diagnostic tests and skin biopsy, we arrived at the diagnosis of acquired localized hypertrichosis secondary to the use of rivastigmine. Given the benign nature of the entity and the absence of symptoms, it was decided to conduct a clinical follow-up, without stopping treatment. The patient has been stable in clinical visits during a period of one year, without presenting extension of the hypertrichosis.

3. Discussion

Hypertrichosis is the excessive hair growth in any area of the skin surface, whereas hirsutism is a distinct entity characterized by the appearance of hair in children and/or women, with an adult male pattern distribution associated with hormonal changes. Hypertrichosis is classified as congenital or acquired, and there are localized and generalized forms. Moreover, hair in hypertrichosis is usually longer than expected and may consist of any hair type (lanugo, vellus, or terminal) [1].

Acquired localized hypertrichosis may be secondary to multiple causes including Becker’s nevus, chemicals, neoplasms, bone fractures, use of casts and splints, trauma, friction, venous malformations, thrombosis, osteomyelitis, HIV, systemic lupus erythematosus, and linear scleroderma [1, 2]. Moreover, there is a secondary form due to drugs, which is usually reversible with discontinuation of the causative agent, and it has been associated with numerous treatments (Table 2) [1–3].

Rivastigmine is a reversible and competitive inhibitor of acetylcholinesterase and butyrylcholinesterase used for symptomatic treatment of Alzheimer dementia and Parkinson’s disease. It can be administered orally or transdermally and it has an adequate safety profile [4]. Side effects are dose dependent and occur in eight to nine percent of patients. Main side effects are gastrointestinal (anorexia, dyspepsia, nausea, vomiting, diarrhea, and abdominal pain) which are usually mild and transient, followed by neurological disorders (asthenia, headache, drowsiness, confusion, anxiety, and agitation) and cardiovascular problems (hypertension and orthostatic hypotension) [4, 5].

Cutaneous side effects are rare, with a frequency of 7% in users of transdermal patches, which are generally mild. However, in approximately 2.5% of the patients, it is necessary to interrupt the medication due to severe skin reactions. Irritant contact dermatitis is the most common cutaneous side effect of rivastigmine patch users. It manifests itself with geometric eczematous lesions, which are located in the area where the transdermal patch was applied. Signs and symptoms of irritant contact dermatitis may be minimized by rotation of the application site, careful removal of the patch, and application of the patch to clean, dry, nonhairy area of healthy skin [4–7].

In addition, there have been some case reports of allergic dermatitis and baboon syndrome (Table 1) [4–11]. These cases have developed a cutaneous rash, without systemic symptoms or laboratory abnormalities. The evolution is self-limited with discontinuation of the drug and sometimes oral or topical corticosteroids associated with oral antihistamines are necessary. Moreover, there have been reports of cross-reactivity with other acetylcholinesterase inhibitors such as galantamine, which have triggered identical skin symptoms [8].

Table 1: Reported cases of adverse skin effects by rivastigmine.

Gender
Age (years)
Route of administration
Latency time until the rash
Diagnosis
Evolution

Golüke et al. [8]
Male
74
Transdermal patch
(9.5 mg/day)
1 year
Localized allergic contact dermatitis
Drug discontinuation
Resolution in days
Recurrence with galantamine

Makris et al. [9]
Female
85
Transdermal patch
(9.5 mg/day)
Oral
(6 mg/day)
3 weeks
Disseminated allergic contact dermatitis
Drug discontinuation
Resolution in 2 weeks

Allain-Veyrac et al. [10]
Male
88
Oral
(3 mg/day)
3 weeks
Baboon syndrome
Drug discontinuation
Resolution in 2 weeks

Greenspoon et al. [6]
Female
65
Transdermal patch
(Dose NA)
Several weeks
Disseminated allergic contact dermatitis
Drug discontinuation
Resolution in several weeks

Grieco et al. [7]
Male
75
Transdermal patch
(9.5 mg/day)
2 weeks
Disseminated allergic contact dermatitis
Drug discontinuation
Resolution time NA

Monastero et al. [11]
Female
73
Oral
(3 mg/day)
5 days
Baboon syndrome
Drug discontinuation
Resolution in 2 weeks

NA: not available.

Table 2: Reported cases of acquired hypertrichosis due to drugs.

Widespread involvement ()
Cyclosporin A
Corticosteroids
Interferon alpha
Penicillin
Streptomycin
Phenytoin
Diphenylhydantoin
Spironolactone
Zidovudine
Acetazolamide
Latanoprost
Bimatoprost
Psoralens
Diazoxide
Minoxidil

Localized involvement
Topical latanoprost
Topical bimatoprost
Topical minoxidil

Usually generalized involvement with scalp, frontal region, trunk, and extremity involvement.

Acetylcholinesterase inhibitors can induce hair growth. Norgalanthamine, a principal extract of the plant Crinum asiaticum, has been shown to promote hair growth activity via the proliferation of dermal papilla [12]. We attribute the cause of hypertrichosis to rivastigmine by the temporal relationship, without finding another possible cause. The patient has not taken any other drugs. He has not been given topical chemicals and the analytical and imaging tests were normal. Rivastigmine was not stopped because it was necessary for the underlying disease, so we could not check the resolution of hypertrichosis.

Competing Interests

The authors have no competing interests to declare.

References

D. S. Wendelin, D. N. Pope, and S. B. Mallory, “Hypertrichosis,” Journal of the American Academy of Dermatology, vol. 48, no. 2, pp. 161–179, 2003.

A. J. E. Vulink and D. T. B. ten Bokkel Huinink, “Acquired hypertrichosis lanuginosa: a rare cutaneous paraneoplastic syndrome,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1625–1626, 2007.

R. Salido, F. J. Gómez-García, G. Garnacho-Saucedo, and M. Galán-Gutiérrez, “Acquired generalized hypertrichosis due to diazoxide,” Actas Dermo-Sifiliograficas, vol. 104, no. 2, pp. 166–167, 2013.

T. Darreh-Shori and V. Jelic, “Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia,” Expert Opinion on Drug Safety, vol. 9, pp. 167–176, 2010.

T. B. Ali, T. R. Schleret, B. M. Reilly, W. Y. Chen, R. Abagyan, and A. Cavalli, “Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada,” PLoS ONE, vol. 10, no. 12, Article ID e0144337, 2015.

J. Greenspoon, N. Herrmann, and D. N. Adam, “Transdermal rivastigmine: management of cutaneous adverse events and review of the literature,” CNS Drugs, vol. 25, no. 7, pp. 575–583, 2011.

T. Grieco, M. Rossi, V. Faina, I. De Marco, P. Pigatto, and S. Calvieri, “An atypical cutaneous reaction to rivastigmine transdermal patch,” Journal of Allergy, vol. 2011, Article ID 752098, 2 pages, 2011.

N. M. S. Golüke, A. M. Van Strien, P. J. L. Dautzenberg, N. Jessurun, and C. J. P. W. Keijsers, “Skin lesions after oral acetylcholinesterase inhibitor therapy: a case report,” Journal of the American Geriatrics Society, vol. 62, no. 10, pp. 2012–2013, 2014.

M. Makris, S. Koulouris, I. Koti, X. Aggelides, and D. Kalogeromitros, “Maculopapular eruption to rivastigmine's transdermal patch application and successful oral desensitization,” Allergy, vol. 65, no. 7, pp. 925–926, 2010.

G. Allain-Veyrac, A. Lebreton, C. Collonnier, and P. Jolliet, “First case of symmetric drug-related intertriginous and flexural exanthema (SDRIFE) due to rivastigmine?” American Journal of Clinical Dermatology, vol. 12, no. 3, pp. 210–213, 2011.

R. Monastero, G. Lopez, M. Mannino, and R. Camarda, “Erythematous maculopapular eruption due to rivastigmine therapy,” American Journal of Medicine, vol. 111, no. 7, pp. 583–584, 2001.

S. C. Kim, J. I. Kang, M. K. Kim et al., “Promotion effect of norgalanthamine, a component of Crinum asiaticum, on hair growth,” European Journal of Dermatology, vol. 20, no. 1, pp. 42–48, 2010.